Labetuzumab govitecan: Phase I/II data

Data from 66 evaluable mCRC patients previously treated with >=1 irinotecan-containing regimen in an open-label, dose-escalation, U.S. Phase I/II trial showed that once- and twice-weekly IMMU-130 for ...